An interventional study of High-level laser therapy and Low-level laser therapy in Lumbar Radiculopathy, sponsored by Riphah International University. Completed at 2 sites in Pakistan. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-05.
Sponsored by Riphah International University · Not applicable, Interventional, and Treatment
To Compare the effects of high-level laser therapy (HLLT) and low-level laser therapy (LLLT) on pain in patients with lumbar radiculopathy.
488 studies on the registry are indexed under Radiculopathy; 141 are open to participants now.
This study's enrollment of 38 is below the median of 60 across 376 interventional studies indexed under Radiculopathy.
Browse Radiculopathy studies →Riphah International University is the lead sponsor of 2,133 studies on the registry; 633 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Other: High-level laser therapy
This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Other: Low-level laser therapy
This group received High-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
This group received Low-level laser therapy along with conventional physiotherapy treatment 3 times per week for 6 weeks.
Pain Level
Visual Analogue scale
Time frame: 6 weeks
Rang of motion
Straight Leg Raise
Time frame: 6 weeks
Level of Disability
Oswestry Disability Index (ODI)
Time frame: 6 weeks
To measure Quality of Life
Health Questionnaire (EQ-5D-5L)
Time frame: 6 weeks
Plan to share: No
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Riphah International University